|
1
|
Schmadeka R, Harmon BE and Singh M:
Triple-negative breast carcinoma: Current and emerging concepts. Am
J Clin Pathol. 141:462–477. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abramson VG, Lehmann BD, Ballinger TJ and
Pietenpol JA: Subtyping of triple-negative breast cancer:
Implications for therapy. Cancer. 121:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Minn AJ, Bevilacqua E, Yun J and Rosner
MR: Identification of novel metastasis suppressor signaling
pathways for breast cancer. Cell Cycle. 11:2452–2457. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hao C, Wei S, Tong Z, Li S, Shi Y, Wang X
and Zhu ZH: The effects of RKIP gene expression on the biological
characteristics of human triple-negative breast cancer cells in
vitro. Tumour Biol. 33:1159–1167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Mulla F, Bitar MS, Thiery JP, Zea TT,
Chatterjee D, Bennett L, Park S, Edwards J and Yeung KC: Clinical
implications for loss or diminution of Raf-1 kinase inhibitory
protein and its phosphorylated form in ductal breast cancer. Am J
Cancer Res. 3:446–464. 2013.PubMed/NCBI
|
|
6
|
Odabaei G, Chatterjee D, Jazirehi AR,
Goodglick L, Yeung K and Bonavida B: Raf-1 kinase inhibitor
protein: Structure, function, regulation of cell signaling and
pivotal role in apoptosis. Adv Cancer Res. 91:169–200. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang H, Park S, Sun SC, Trumbly R, Ren G,
Tsung E and Yeung KC: RKIP inhibits NF-kappaB in cancer cells by
regulating upstream signaling components of the IkappaB kinase
complex. FEBS Lett. 584:662–668. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yousuf S, Duan M, Moen EL, Cross-Knorr S,
Brilliant K, Bonavida B, LaValle T, Yeung KC, Al-Mulla F, Chin E
and Chatterjee D: Raf kinase inhibitor protein (RKIP) blocks signal
transducer and activator of transcription 3 (STAT3) activation in
breast and prostate cancer. PLoS One. 9:e924782014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eves EM, Shapiro P, Naik K, Klein UR,
Trakul N and Rosner MR: Raf kinase inhibitory protein regulates
aurora B kinase and the spindle checkpoint. Mol Cell. 23:561–574.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klysik J, Theroux SJ, Sedivy JM, Moffit JS
and Boekelheide K: Signaling crossroads: The function of Raf kinase
inhibitory protein in cancer, the central nervous system and
reproduction. Cell Signal. 20:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Poma P, Labbozzetta M, Vivona N, Porcasi
R, D'Alessandro N and Notarbartolo M: Analysis of possible
mechanisms accounting for raf-1 kinase inhibitor protein
downregulation in hepatocellular carcinoma. OMICS. 16:579–588.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jazirehi AR and Bonavida B: Cellular and
molecular signal transduction pathways modulated by rituximab
(rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in
chemosensitization and therapeutic intervention. Oncogene.
24:2121–2143. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu YL, Chen CY, Lin IP, Tsai EM, Kuo PL
and Hou MF: 4-Shogaol, an active constituent of dietary ginger,
inhibits metastasis of MDA-MB-231 human breast adenocarcinoma cells
by decreasing the repression of NF-κB/Snail on RKIP. J Agric Food
Chem. 60:852–861. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen TC, Hsu YL, Tsai YC, Chang YW, Kuo PL
and Chen YH: Gemifloxacin inhibits migration and invasion and
induces mesenchymal-epithelial transition in human breast
adenocarcinoma cells. J Mol Med (Berl). 92:53–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren G, Baritaki S, Marathe H, Feng J, Park
S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, et al:
Polycomb protein EZH2 regulates tumor invasion via the
transcriptional repression of the metastasis suppressor RKIP in
breast and prostate cancer. Cancer Res. 72:3091–3104. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang L, Dai T, Lin X, Zhao X, Chen X,
Wang C, Li X, Shen H and Wang X: MicroRNA-224 targets RKIP to
control cell invasion and expression of metastasis genes in human
breast cancer cells. Biochem Biophys Res Commun. 425:127–133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou TC and Talalay P: Analysis of
combined drug effects: A new look at a very old problem. Trends
Pharmacol Sci. 4:450–454. 1983. View Article : Google Scholar
|
|
18
|
Florena AM, Tripodo C, Guarnotta C, Ingrao
S, Porcasi R, Martorana A, Lo Bosco G, Cabibi D and Franco V:
Associations between Notch-2, Akt-1 and HER2/neu expression in
invasive human breast cancer: A tissue microarray immunophenotypic
analysis on 98 patients. Pathobiology. 74:317–322. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Notarbartolo M, Giannitrapani L, Vivona N,
Poma P, Labbozzetta M, Florena AM, Porcasi R, Muggeo VM, Sandonato
L and Cervello M: Frequent alteration of the Yin Yang 1/Raf-1
kinase inhibitory protein ratio in hepatocellular carcinoma. OMICS.
15:267–272. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Neve RM, Chin K, Fridlyand J, Baehner FL,
Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schuierer MM, Bataille F, Weiss TS,
Hellerbrand C and Bosserhof AK: Raf kinase inhibitor protein is
down-regulated in hepatocellular carcinoma. Oncol Rep. 16:451–456.
2006.PubMed/NCBI
|
|
22
|
Minoo P, Zlobec I, Baker K, Tornillo L,
Terracciano L, Jass JR and Lugli A: Loss of raf-1 kinase inhibitor
protein expression is associated with tumor progression and
metastasis in colorectal cancer. Am J Clin Pathol. 127:820–827.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Al-Mulla F, Hagan S, Al-Ali W, Jacob SP,
Behbehani AI, Bitar MS, Dallol A and Kolch W: Raf kinase inhibitor
protein: Mechanism of loss of expression and association with
genomic instability. J Clin Pathol. 61:524–529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li DX, Cai HY, Wang X, Feng YL and Cai SW:
Promoter methylation of Raf kinase inhibitory protein: A
significant prognostic indicator for patients with gastric
adenocarcinoma. Exp Ther Med. 8:844–850. 2014.PubMed/NCBI
|
|
25
|
Minoo P, Baker K, Goswami R, Chong G,
Foulkes WD, Ruszkiewicz AR, Barker M, Buchanan D, Young J and Jass
JR: Extensive DNA methylation in normal colorectal mucosa in
hyperplatic polyposis. Gut. 55:1467–1474. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Connolly R and Stearns R: Epigenetics as a
therapeutic target in breast cancer. J Mammary Gland Biol
Neoplasia. 17:191–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu K and Bonavida B: The activated
NF-kappaB-Snail-RKIP circuitry in cancer regulates both the
metastatic cascade and resistance to apoptosis by cytotoxic drugs.
Crit Rev Immunol. 29:241–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Umezawa K: Possible role of peritoneal
NF-κB in peripheral inflammation and cancer: Lessons from the
inhibitor DHMEQ. Biomed Pharmacother. 65:252–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Poma P, Notarbartolo M, Labbozzetta M,
Sanguedolce R, Alaimo A, Carina V, Maurici A, Cusimano A, Cervello
M and D'Alessandro N: Antitumor effects of the novel NF-kappaB
inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer
cells: Analysis of synergy with cisplatin and of possible
correlation with inhibition of pro-survival genes and IL-6
production. Int J Oncol. 28:923–930. 2006.PubMed/NCBI
|
|
30
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fabbri M and Calin GA: Epigenetics and
miRNAs in human cancer. Adv Genet. 70:87–99. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Inguglia L, Notarbartolo M, Poma P,
Labbozzetta M and D'Alessandro N: Induction of apoptosis and
chemosensitization by the histone deacetylase inhibitor
trichostatin A in hepatocellular carcinoma cells: Molecular
analysis and RKIP levels. Forum Immun Dis Ther. 2:127–135. 2011.
View Article : Google Scholar
|
|
33
|
Yang X, Phillips DL, Ferguson AT, Nelson
WG, Herman JG and Davidson NE: Synergistic activation of functional
estrogen receptor (ER)-alpha by DNA methyltransferase and histone
deacetylase inhibition in human ER-alpha-negative breast cancer
cells. Cancer Res. 61:7025–7029. 2001.PubMed/NCBI
|
|
34
|
Zhai FX, Liu XF, Fan RF, Long ZJ, Fang ZG,
Lu Y, Zheng YJ and Lin DJ: RUNX3 is involved in caspase-3-dependent
apoptosis induced by a combination of 5-aza-CdR and TSA in
leukaemia cell lines. J Cancer Res Clin Oncol. 138:439–449. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sethi S, Sarkar FH, Ahmed Q, Bandyopadhyay
S, Nahleh ZA, Semaan A, Sakr W, Munkarah A and Ali-Fehmi R:
Molecular markers of epithelial-to-mesenchymal transition are
associated with tumor aggressiveness in breast carcinoma. Transl
Oncol. 4:222–226. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Piao HL, Yuan Y, Wang M, Sun Y, Liang H
and Ma L: α-catenin acts as a tumour suppressor in
E-cadherin-negative basal-like breast cancer by inhibiting NF-κB
signalling. Nat Cell Biol. 16:245–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Walker EJ, Rosenberg SA, Wands JR and Kim
M: Role of raf kinase inhibitor protein in hepatocellular
carcinoma. For Immunopathol Dis Therap. 2:195–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
